XML 40 R31.htm IDEA: XBRL DOCUMENT v3.22.2
Description of Operations and Summary of Significant Accounting Policies (Details) - USD ($)
$ in Thousands
6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Description of Operations and Summary of Significant Accounting Policies      
Decrease to accumulated deficit $ 37,200    
Reduction to Additional Paid in Capital 65,400    
Equity and long-term investments 494,097   $ 483,845
Purchases of equity investments managed by ISP Fund LP (38,026) $ (142,636)  
Sale of equity investments managed by ISP Fund LP 24,281 18,545  
Purchase and sales of other investments managed by ISP Fund LP, net 96,255 (234,091)  
Increase in Deferred Tax Assets 7,400    
Prior Period Immaterial Correction      
Description of Operations and Summary of Significant Accounting Policies      
Purchases of equity investments managed by ISP Fund LP   (142,600)  
Sale of equity investments managed by ISP Fund LP   18,500  
Purchase and sales of other investments managed by ISP Fund LP, net   $ 234,100  
Convertible senior notes      
Description of Operations and Summary of Significant Accounting Policies      
Increase in convertible notes $ 35,600    
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK      
Description of Operations and Summary of Significant Accounting Policies      
Percentage of economic interest in any future payments made under the agreements 15.00%    
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | RELVAR/BREO      
Description of Operations and Summary of Significant Accounting Policies      
Royalty rate for first level of annual global net sales (as a percent) 15.00%    
Annual global sales level used to determine royalty rate $ 3,000,000    
Royalty rate for sales above first level of annual global net sales (as a percent) 5.00%    
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | ANORO | Minimum      
Description of Operations and Summary of Significant Accounting Policies      
Royalty rate for combination products (as a percent) 6.50%    
Long-Acting Beta2 Agonist (LABA) Collaboration | GSK | ANORO | Maximum      
Description of Operations and Summary of Significant Accounting Policies      
Royalty rate for combination products (as a percent) 10.00%